Enzaplatovir

CAS No. 1323077-89-9

Enzaplatovir( —— )

Catalog No. M34242 CAS No. 1323077-89-9

Enzaplatovir (BTA-585) is an orally available fusion inhibitor with antiviral activity for the study of respiratory syncytial virus infections and coronavirus disease (COVID-19) infections.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 327 Get Quote
5MG 511 Get Quote
10MG 825 Get Quote
25MG 1398 Get Quote
50MG 1822 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Enzaplatovir
  • Note
    Research use only, not for human use.
  • Brief Description
    Enzaplatovir (BTA-585) is an orally available fusion inhibitor with antiviral activity for the study of respiratory syncytial virus infections and coronavirus disease (COVID-19) infections.
  • Description
    Enzaplatovir (BTA-C585) is an orally bioavailable Inhibitor for respiratory syncytial virus (RSV) infection.
  • In Vitro
    Respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) imposes a substantial medical burden. Enzaplatovir is a small-molecule RSV entry inhibitor.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    JAK/STAT Signaling
  • Target
    STAT
  • Recptor
    RSV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1323077-89-9
  • Formula Weight
    377.4
  • Molecular Formula
    C20H19N5O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 200 mg/mL (529.94 mM; Ultrasonic )
  • SMILES
    Cc1nocc1C(=O)N1CCN2C(=O)c3cccn3C[C@]12c1ccc(C)nc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Eric A F Sim?es, et al. Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children. Infect Dis Ther. 2018 Mar;7(1):87-120.?
molnova catalog
related products
  • Piperlongumine

    A naturally occurring small molecule recently identified to be toxic selectively to cancer cells in vitro and in vivo.

  • CMD178 TFA

    CMD178 (TFA) is a lead peptide that consistently reduces the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling.

  • HO-3867

    A synthetic curcuminoid that selectively inhibits STAT3 phosphorylation, transcription, and DNA binding without affecting the expression of other active STATs.